Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor

[1]  Adam L. Halberstadt,et al.  Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens , 2011, Neuropharmacology.

[2]  J. C. Winter,et al.  Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. , 2010, Current drug metabolism.

[3]  A. Yu,et al.  Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. , 2010, Biochemical pharmacology.

[4]  G. Koob,et al.  Encyclopedia of Behavioral Neuroscience , 2010 .

[5]  Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule. , 2010, Federal register.

[6]  M. Geyer,et al.  Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors , 2008, Psychopharmacology.

[7]  H. Steinbusch,et al.  Hypomobility after DOI administration can be reversed by subthalamic nucleus deep brain stimulation , 2007, Behavioural Brain Research.

[8]  Felix Hasler,et al.  Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans , 2007, Psychopharmacology.

[9]  J. Horáček,et al.  Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose , 2007, Psychopharmacology.

[10]  M. Geyer,et al.  The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats , 2006, Psychopharmacology.

[11]  M. Geyer,et al.  Dissociation of multiple effects of acute LSD on exploratory behavior in rats by ritanserin and propranolol , 2006, Psychopharmacology.

[12]  B. Levine,et al.  A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. , 2005, Journal of analytical toxicology.

[13]  David C. Burr,et al.  Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors , 2005, Journal of Cognitive Neuroscience.

[14]  S. Esteban,et al.  High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain. , 2005, European journal of pharmacology.

[15]  S. Szára.  6-Hydroxylation: An important metabolic route for α-methyltryptamine , 1961, Experientia.

[16]  J. Axelrod,et al.  Hydroxylation and N-demethylation of N,N-dimethyltryptamine , 1959, Experientia.

[17]  M. Geyer,et al.  A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants , 2005, Psychopharmacology.

[18]  M. Geyer,et al.  5HT-2 mediation of acute behavioral effects of hallucinogens in rats , 2005, Psychopharmacology.

[19]  E. Boyer,et al.  Monoamine Oxidase Inhibitor Poisoning Resulting from Internet Misinformation on Illicit Substances , 2004, Journal of toxicology. Clinical toxicology.

[20]  M. Geyer,et al.  A characteristic effect of hallucinogens on investigatory responding in rats , 1979, Psychopharmacology.

[21]  H. Nakano.  [Monoamine oxidase]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[22]  R. Glennon,et al.  Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens , 2004, Psychopharmacology.

[23]  P. Waldmeier,et al.  Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors , 2004, Psychopharmacology.

[24]  J. Idle,et al.  Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. , 2003, Pharmacogenetics.

[25]  D. Nutt,et al.  β-carboline binding to imidazoline receptors , 2001 .

[26]  A. Grottick,et al.  Effect of LSD on Prepulse Inhibition and Spontaneous Behavior in the Rat: A Pharmacological Analysis and Comparison between Two Rat Strains , 2001, Neuropsychopharmacology.

[27]  J. Ott.  Pharmepéna-Psychonautics: Human Intranasal, Sublingual and Oral Pharmacology of 5-Methoxy-N, N-Dimethyl-Tryptamine , 2001, Journal of psychoactive drugs.

[28]  B. Roth,et al.  Agonist high and low affinity state ratios predict drug intrinsic activity and a revised Ternary complex mechanism at serotonin 5‐HT2A and 5‐HT2C receptors , 2000, Synapse.

[29]  M. Geyer,et al.  Increased Exploratory Activity and Altered Response to LSD in Mice Lacking the 5-HT5A Receptor , 1999, Neuron.

[30]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[31]  Martin P Paulus,et al.  Effects of Hallucinogens on Locomotor and Investigatory Activity and Patterns: Influence of 5-HT2A and 5-HT2C Receptors , 1998, Neuropsychopharmacology.

[32]  B. Roth,et al.  High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. , 1997, The Journal of pharmacology and experimental therapeutics.

[33]  Alexander T. Shulgin,et al.  Tihkal : The Continuation , 1997 .

[34]  B. Levant,et al.  Modulation of [3H]quinpirole binding in brain by monoamine oxidase inhibitors: evidence for a potential novel binding site. , 1996, The Journal of pharmacology and experimental therapeutics.

[35]  D. Nutt,et al.  [3H]2-(2-benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors. , 1996, European journal of pharmacology.

[36]  R. Glennon,et al.  Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines. , 1994, Journal of medicinal chemistry.

[37]  R. Glennon,et al.  Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. , 1992, Journal of medicinal chemistry.

[38]  F. Fosberg,et al.  The Healing Forest: Medicinal and Toxic Plants of the Northwest Amazonia , 1991 .

[39]  Y. Itzhak,et al.  Clorgyline displays high affinity for σ binding sites in C57BL/6 mouse brain , 1990 .

[40]  R. Schultes.  The healing forest , 1990 .

[41]  M. Adler,et al.  Testing and evaluation of drugs of abuse , 1990 .

[42]  R. Glennon,et al.  Iodine-125 labeled 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors , 1988 .

[43]  B. R. Sitaram,et al.  In vivo metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat. , 1987, Biochemical pharmacology.

[44]  B. R. Sitaram,et al.  Study of metabolism of psychotomimetic indolealkylamines by rat tissue extracts using liquid chromatography. , 1987, Biochemical pharmacology.

[45]  M. Titeler,et al.  3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors. , 1987, Molecular pharmacology.

[46]  A. Boulton,et al.  Effect of deuterium substitution on the disposition of intraperitoneal tryptamine. , 1986, Biochemical pharmacology.

[47]  Patrick V. Russo,et al.  Multivariate assessment of locomotor behavior: Pharmacological and behavioral analyses , 1986, Pharmacology Biochemistry and Behavior.

[48]  M. Geyer,et al.  Effects of DOM and DMT in a proposed animal model of hallucinogenic activity , 1985, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[49]  M. Geyer,et al.  A proposed animal model for hallucinogens based on LSD's effects on patterns of exploration in rats. , 1985, Behavioral neuroscience.

[50]  J. Monti,et al.  In vivo metabolism of α,α,β,β-tetradeutero-n, N-dimethyltryptamine in rodent brain , 1984 .

[51]  D. Mckenna,et al.  Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca. , 1984, Journal of ethnopharmacology.

[52]  F. J. White,et al.  Comparison of the effects of LSD and lisuride on A10 dopamine neurons in the rat , 1983, Neuropharmacology.

[53]  J. Monti,et al.  Comparison of the brain levels of N,N-dimethyltryptamine and alpha, alpha, beta, beta-tetradeutero-N-N-dimethyltryptamine following intraperitoneal injection. The in vivo kinetic isotope effect. , 1982, Biochemical pharmacology.

[54]  S. Barker,et al.  A comparison of the behavioral effects of proteo- and deutero-N, N-dimethyltryptamine , 1982, Pharmacology Biochemistry and Behavior.

[55]  R. Schultes,et al.  Indole Alkaloids in Amazonian Myristicaceae: Field And Laboratory Research , 1980, Botanical Museum leaflets, Harvard University.

[56]  G. Milne,et al.  Mass spectra of some specifically deuterated tryptamines. , 1977, Biomedical mass spectrometry.

[57]  B. Jacobs,et al.  Electrophysiological evidence for a dopaminergic action of LSD: depression of unit activity in the substantia nigra of the rat. , 1977, Life sciences.

[58]  T. Yamamoto,et al.  Behavioral effects of 2,5-dimethoxy-4-methylamphetamine (DOM) in rats and mice. , 1975, European journal of pharmacology.

[59]  R. Squires.  EVIDENCE THAT 5‐METHOXY‐N, N‐DIMETHYL TRYPTAMINE IS A SPECIFIC SUBSTRATE FOR MAO‐A IN THE RAT: IMPLICATIONS FOR THE INDOLEAMINE DEPENDENT BEHAVIOURAL SYNDROME , 1975, Journal of neurochemistry.

[60]  R. Schultes,et al.  The Botany and Chemistry of Hallucinogens , 1974 .

[61]  J. Lindgren,et al.  Metabolism of 5-methoxy-N,-N dimethyltryptamine- 14 C in the rat. , 1969, Biochemical pharmacology.

[62]  J. Lindgren,et al.  Alkaloid content of Banisteriopsis rusbyana. , 1968, American journal of pharmacy and the sciences supporting public health.

[63]  B. Pitt.  Psychopharmacology , 1968, Mental Health.

[64]  E. Hearst,et al.  Metabolism and behavioural action of psychotropic tryptamine homologues , 1962 .

[65]  H. Weissbach,et al.  The fate of melatonin in animals. , 1961, The Journal of biological chemistry.

[66]  I. Page,et al.  The relationship between the metabolic fate and pharmacological actions of serotonin, bufotenine and psilocybin. , 1960, The Journal of pharmacology and experimental therapeutics.